Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero
Top Cited Papers
Open Access
- 1 September 2006
- Vol. 107 (6), 1219-1226
- https://doi.org/10.1002/cncr.22081
Abstract
BACKGROUND As women in the US delay childbearing, it has been hypothesized that the incidence of breast cancer diagnosed during pregnancy will increase. There are very little prospective data on the treatment of pregnant women with breast cancer with chemotherapy and even less data on the outcomes of their children who were exposed to chemotherapy in utero. METHODS Fifty‐seven pregnant breast cancer patients were treated on a single‐arm, multidisciplinary, institutional review board‐approved protocol with FAC (5‐fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant (n = 32) or neoadjuvant (n = 25) setting. Parents/guardians were surveyed by mail or telephone regarding outcomes of children exposed to chemotherapy in utero. RESULTS Of the 57 women, 40 are alive and disease‐free, 3 have recurrent breast cancer, 12 died from breast cancer, 1 died from other causes, and 1 was lost to follow‐up. Of the 25 patients who received neoadjuvant FAC, 6 had a pathologic complete response, whereas 4 had no tumor response to chemotherapy and eventually died from their disease. All women who delivered had live births. One child has Down syndrome and 2 have congenital anomalies (club foot; congenital bilateral ureteral reflux). The children are healthy and those in school are doing well, although 2 have special educational needs. CONCLUSIONS Breast cancer can be treated with FAC chemotherapy during the second and third trimesters without significant short‐term complications for the majority of children exposed to chemotherapy in utero. Longer follow‐up of the children is needed to evaluate possible late side effects such as impaired cardiac function and fertility. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 47 references indexed in Scilit:
- Efficacy of Pegfilgrastim and Darbepoetin Alfa As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer ChemotherapyJournal of Clinical Oncology, 2005
- Chemotherapy for Breast Cancer During Pregnancy: An 18-Year Experience From Five London Teaching HospitalsJournal of Clinical Oncology, 2005
- HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and youngerCancer, 2005
- Breast carcinoma in pregnant womenCancer, 2003
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Severe chronic neutropenia: Treatment and follow‐up of patients in the Severe Chronic Neutropenia International RegistryAmerican Journal of Hematology, 2003
- Clinicopathologic Characteristics and Prognosis of Breast Cancer Patients Associated with Pregnancy and Lactation: Analysis of Case‐Control Study in JapanJapanese Journal of Cancer Research, 1992
- Mammary cancers and pregnancy.BMJ, 1979
- Treatment of Breast Tumors Associated with Pregnancy and Lactation*Annals of Surgery, 1962
- Prognosis of Breast Cancer for Pregnant and Nursing WomenActa Obstetricia et Gynecologica Scandinavica, 1946